Ticker LaunchLondon · Main Market · IPO · MXC
MGC Pharmaceuticals
MGC Pharmaceuticals (MXC) was admitted to Main Market on Feb 9, 2021, raising £6.5M at 1.47p per share. Its market capitalization at admission was about £33.7M. Brokers: Turner Pope Investments Limited (sole lead manager and bookrunner).
MGC Pharmaceuticals is a European-based, Australian-listed bio-pharma company that produces and develops phytocannabinoid-derived medicines, including ArtemiC and CannEpil, with a focus on neurology, oncology and autoimmune diseases.
- Type
- IPO
- Market
- Main Market · Standard
- Ticker (TIDM)
- MXC
- Admitted
- Feb 9, 2021
- Offer price
- 1.47p
- Raised
- £6.5M
- Market cap at admission
- £33.7M
- Brokers
- Turner Pope Investments Limited (sole lead manager and bookrunner)
- Sector
- Biotech & pharma
- Country
- Australia
More on this listing for subscribers
- Intention-to-float date
- New money versus sale shares
- Shares in issue at admission
- Source announcements
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Sources
From company announcements filed with the FCA's National Storage Mechanism. Subscribers see the list of announcements for each listing.
Other London listings around the same time
- Cornish Metals Inc.AIM · Feb 16, 2021
- Cordiant Digital Infrastructure LimitedMain Market · Feb 16, 2021
- Foresight Group Holdings LimitedMain Market · Feb 9, 2021
- Moonpig Group plcMain Market · Feb 5, 2021
- Dr. Martens plcMain Market · Feb 3, 2021
- VH Global Sustainable Energy Opportunities plcMain Market · Feb 2, 2021